Home > Healthcare > Medical Devices > Diagnostic Devices > In-Vitro Colorectal Cancer Screening Tests Market

In-Vitro Colorectal Cancer Screening Tests Market Share

Report ID: GMI451
Published Date: Oct 2021
Report Format: PDF

Download Free Sample

In-Vitro Colorectal Cancer Screening Tests Market Share

Some of the major companies operating in the in-vitro colorectal cancer screening tests market are:

Abbott Molecular
Epigenomics AG
Novigenix
Sysmex Corporation
Eiken Chemical
Quest Diagnostics
BioMarCare Technologies
Randox Laboratories
OncoCyte Corporation-Bio time
Exact Sciences Corporation
Immunostics.

These prominent leaders concentrate on adoption of several initiatives such as strategic agreements, new product launch, mergers & acquisition for business expansion. Furthermore, these participants are heavily investing in research that enables them to launch advanced products and channelize maximum market share.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The global market size of in-vitro colorectal cancer screening tests was worth USD 765 million in 2020 and will witness a growth rate of around 5.9% through 2027 owing to the increasing adoption of unhealthy lifestyles and the rising burden of colorectal cancer (CRC).

Fecal occult blood tests, biomarker tests, and CRC DNA screening tests are some of the well-known tests used for in-vitro colorectal cancer screening.

The U.S. market is estimated to exceed USD 392 million through 2027 due to the rising prevalence of obesity and CRC, along with the presence of favorable reimbursement scenarios in the country.